157 related articles for article (PubMed ID: 33637109)
1. CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma.
Šutić M; Baranašić J; Bilić LK; Bilić M; Jakovčević A; Brčić L; Seiwerth S; Jakopović M; Samaržija M; Zechner U; Knežević J
Diagn Pathol; 2021 Feb; 16(1):17. PubMed ID: 33637109
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
3. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma.
Lleras RA; Smith RV; Adrien LR; Schlecht NF; Burk RD; Harris TM; Childs G; Prystowsky MB; Belbin TJ
Clin Cancer Res; 2013 Oct; 19(19):5444-55. PubMed ID: 23894057
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
5. Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.
Demokan S; Chuang AY; Pattani KM; Sidransky D; Koch W; Califano JA
Oncol Rep; 2014 Feb; 31(2):1014-20. PubMed ID: 24337411
[TBL] [Abstract][Full Text] [Related]
6. Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue.
Bhat S; Kabekkodu SP; Jayaprakash C; Radhakrishnan R; Ray S; Satyamoorthy K
Virchows Arch; 2017 Apr; 470(4):445-454. PubMed ID: 28255813
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.
Cao W; Zhang ZY; Xu Q; Sun Q; Yan M; Zhang J; Zhang P; Han ZG; Chen WT
Mol Cancer; 2010 Nov; 9():296. PubMed ID: 21092172
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
11. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC).
Smiraglia DJ; Smith LT; Lang JC; Rush LJ; Dai Z; Schuller DE; Plass C
J Med Genet; 2003 Jan; 40(1):25-33. PubMed ID: 12525538
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.
Zhou C; Li J; Li Q; Liu H; Ye D; Wu Z; Shen Z; Deng H
J Clin Lab Anal; 2019 Jun; 33(5):e22873. PubMed ID: 30843252
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation biomarkers for head and neck squamous cell carcinoma.
Zhou C; Ye M; Ni S; Li Q; Ye D; Li J; Shen Z; Deng H
Epigenetics; 2018; 13(4):398-409. PubMed ID: 29927694
[TBL] [Abstract][Full Text] [Related]
14. Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
Zolk O; Schnepf R; Muschler M; Fromm MF; Wendler O; Traxdorf M; Iro H; Zenk J
Am J Pathol; 2013 Jan; 182(1):234-43. PubMed ID: 23137910
[TBL] [Abstract][Full Text] [Related]
15. Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma.
Cao Y; Green K; Quattlebaum S; Milam B; Lu L; Gao D; He H; Li N; Gao L; Hall F; Whinery M; Handley E; Ma Y; Xu T; Jin F; Xiao J; Wei M; Smith D; Bornstein S; Gross N; Pyeon D; Song J; Lu SL
Clin Epigenetics; 2018; 10():43. PubMed ID: 29636832
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
17. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
19. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.
Calmon MF; Rodrigues RV; Kaneto CM; Moura RP; Silva SD; Mota LD; Pinheiro DG; Torres C; de Carvalho AF; Cury PM; Nunes FD; Nishimoto IN; Soares FA; da Silva AM; Kowalski LP; Brentani H; Zanelli CF; Silva WA; Rahal P; Tajara EH; Carraro DM; Camargo AA; Valentini SR
Neoplasia; 2009 Dec; 11(12):1329-39. PubMed ID: 20019841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
